Array 10-K2017 FY Annual report

Filed: 11 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Australia, BICR, biliary, binimetininb, BMS, bona, CAGR, Carlo, Central, CK, classical, cobimetinib, content, Cotellic, deep, detachment, Distinguishing, Dohme, EMA, encumber, epithelial, escrow, fall, fide, fifteen, floating, fourteen, Fourteenth, Friday, GGT, goodwill, Hodgkin, hypothetical, implied, incurrance, instability, instable, isolation, Japanese, larotrectinib, lesser, Madrid, mandatorily, Mekinst, Merkel, microsatellite, Monte, MSI, MSS, navigating, noncontrolling, nonpublic, Offshore, Opdivo, ourself, Phenotypic, pigment, promissory, promptly, proportionate, reborrowed, reconcile, Redmile, repay, Republic, retinal, rollforward, scenario, Sharp, Silicon, simulation, sixty, Squibb, stability, standing, straight, Subordinated, subsidiary, succumb, summer, SVB, Territory, thereon, thereunder, tiered, tract, tucatinib, undisclosed, undrawn, unrestricted, unused, unusued, urothelial, Valley, whicth, Yen, Yervoy

Removed: accompanied, accumulate, activated, addressed, AfFIRM, affirmative, alpha, amplified, anemia, augment, bacterial, baseline, bleeding, bortezomib, carfilzomib, Center, chose, covenant, decade, deposition, destruction, dexamethasone, distinct, docetaxel, dosed, East, elderly, ERK, evident, expectancy, fatal, fight, formation, France, garner, heavy, hematologic, hematological, Herceptin, hypercalcemia, Ig, IMiD, immunoglobulin, incurable, infection, Italy, KSP, lenalidomide, locally, main, malignancy, marrow, Mekinist, mentioned, merger, MILO, month, moved, mutant, mutated, myeloma, myelosuppression, Myelosupression, neoplastic, osteolytic, osteopenia, ovarian, paraprotein, plasma, pomalidomide, Pomalyst, Preclinically, premium, pretreated, priced, problem, proliferate, proliferation, proteasome, pursue, recurrent, renal, renewal, resistant, Revlimid, secured, statistically, stem, sublimit, supersede, synergistically, synergy, thalidomide, Thalomid, toxicity, trastuzumab, uptake, Velcade, vivo, walk

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Array similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Array BioPharma Inc.:

We consent to the incorporation by reference in the registration statements (Form S‑3 Nos. 333‑206525 and 333‑189048, and Form S‑8 Nos. 333‑206522, 333‑186383, 333‑178168, 333‑171361, 333‑163138, 333‑158624, 333‑155219, 333‑139450, 333‑132205, 333‑100955, and 333‑51348) of Array BioPharma Inc. of our reports dated August 11, 2017, with respect to the balance sheets of Array BioPharma Inc. as of June 30, 2017 and 2016, and the related statements of operations and comprehensive income (loss), stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended June 30, 2017, and the effectiveness of internal control over financial reporting as of June 30, 2017, which reports appear in the June 30, 2017 annual report on Form 10‑K of Array BioPharma Inc.

/s/ KPMG LLP

Boulder, Colorado

August 11, 2017